Since its discovery in 1979 by Wang et al. [1] prostate specific antigen (PSA) has become the gold standard biomarker for screening, diagnosis, and therapeutic monitoring of prostate cancer (PC), and a routine clinical parameter for the management of benign hyperplasia and inflammatory disorders of the prostate [2–7]. This evidence concerns the gene KLK3 and Familial prostate cancer.